血漿蛋白治療市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、應用、最終用戶、地區及競爭格局分類，2021-2031年）

全球血漿蛋白治療市場預計將從 2025 年的 332.6 億美元成長到 2031 年的 492.7 億美元，複合年成長率為 6.77%。

這些透過分離人類血漿所獲得的生物製劑對於治療罕見、慢性且危及生命的疾病至關重要，例如原發性免疫力缺乏和血友病。市場成長的主要促進因素是：需要終身替代療法的神經系統和免疫系統疾病確診病例不斷增加，以及全球人口老化導致持續醫療照護需求上升。此外，診斷技術的進步也使得特殊患者群體持續擴大，因此需要穩定成長的產量，而這種產量成長不受短期消費模式的影響。

市場擴張的一大障礙在於難以維持穩健的供應鏈。目前，原料採集高度依賴特定地理區域，這種集中化帶來了監管變化和物流中斷等風險，可能威脅全球供應穩定。根據血漿蛋白治療協會預測，到2025年，北美捐贈者將提供全球超過63%的血漿用於生產。因此，實現區域自給自足仍然是穩定市場和滿足日益成長的國際需求的一大挑戰。

市場促進因素

全球對免疫球蛋白療法的需求不斷成長，是推動市場成長的關鍵因素。這主要得益於免疫球蛋白（IG）在原發性和續發性免疫力缺乏治療中應用日益廣泛。隨著診斷率的提高以及在慢性脫髓鞘多發性神經炎（CIDP）等神經系統疾病中臨床應用的拓展，患者對這些終身療法的依賴性日益增強。製造商發現，靜脈注射和皮下注射製劑的需求都在不斷成長，因此需要提高產能以滿足不斷成長的患者群體需求，避免供不應求。 CSL有限公司在其2025年2月發布的「2025會計年度上半年業績報告」中也印證了這一趨勢，報告顯示其免疫球蛋白產品組合的銷售額達到31.7億美元，較上一會計年度成長15%。這凸顯了免疫球蛋白在主要市場參與者財務成長中所扮演的重要角色。

同時，隨著產業規模的擴大，為確保血漿分離所需的原料供應，拓展全球血漿採集基礎設施至關重要。各公司正大力投資擴大捐獻中心網路並最佳化供應鏈物流，以降低對區域的依賴性並提高採集量。這種結構性發展對於穩定生產凝血因子和白蛋白等治療藥物所需的血漿量至關重要。例如，《富比士》在其2025年2月發表的題為《了解武田的血漿衍生治療生態系》的報導中指出，武田每年採集超過1500萬升血漿以滿足生產需求。此外，市場的財務韌性也顯而易見：格里福斯在2025年2月發布的「2024年第四季及全年業績」中報告稱，其年度總收入為72億歐元。

市場挑戰

限制全球血漿蛋白治療市場發展的關鍵障礙之一是供應鏈不穩定，這源自於對特定地理區域採集原血漿的過度依賴。這種高度集中的依賴造成了高風險的瓶頸，全球產品供應不成比例地依賴單一區域的營運連續性。因此，這些關鍵供應區域的政策變化或物流中斷都可能導致全球供不應求，並阻礙製造商擴大生產規模以滿足日益成長的救命療法需求。

這種嚴重的基建不平衡嚴重阻礙了該行業實現原料來源多元化的努力。血漿蛋白治療協會 (PPTA) 的數據凸顯了這種差距：截至 2024 年，血液採集格局極不均衡，光是德克薩斯州就擁有 178 個血漿中心，而整個歐洲大陸也只有 177 個。這種鮮明的對比凸顯了該市場對區域限制的脆弱性。除非血液採集能力不再受地域限制，否則該產業將難以確保維持全球市場擴張所需的穩定供應。

市場趨勢

皮下注射免疫球蛋白療法的興起正在從根本上改變市場格局，將治療模式從醫療機構轉移到靈活的居家照護環境中。這項轉變得益於高濃度製劑的研發，使原發性免疫力缺乏患者能夠自行給藥，顯著提高患者的生活品質，同時減輕醫院的後勤負擔。隨著人們對更便捷給藥方式的需求日益成長，製造商正在推出方便用戶使用的給藥系統，加速免疫球蛋白領域除傳統靜脈注射注射之外的其他領域的發展。根據CSL有限公司於2025年2月公佈的「2025會計年度上半年」財務業績，皮下注射免疫球蛋白產品HIZENTRA的銷售額年增16%，這主要得益於預充式預填充式注射器的日益普及。

同時，採用先進的層析法分離技術來最大限度地提高每公升血漿中的蛋白質回收率已成為關鍵趨勢。面對不斷上漲的原料成本，各公司正迅速採用自動化純化製程來提高高價值蛋白質的產量，使產量與血漿採集量的線性成長脫鉤。這種對營運效率的策略性關注使生產商能夠降低每克蛋白質的成本並提高盈利，從而確保在捐血市場波動的情況下也能獲得利潤。根據 Grifols 公司於 2025 年 2 月發布的“2024 年第四季及全年業績報告”，該公司第四季的調整後EBITDA獲利率為 26.6%。這項業績主要歸功於產量的持續提升以及營運最佳化策略的成功實施。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球血漿蛋白治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品（免疫球蛋白、白蛋白、血漿衍生凝血因子、纖維蛋白原、其他）
  • 依應用（血友病、原發性免疫力缺乏(PID)、特發性血小板減少紫斑症(ITP) 等）
  • 依最終用戶（醫院、研究機構、獨立血庫等）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美血漿蛋白療法市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲血漿蛋白療法市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區血漿蛋白治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲血漿蛋白治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲血漿蛋白療法市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球血漿蛋白治療市場：SWOT分析

第14章 波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Grifols, SA
• CSL Behring AG
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxalta Incorporated
• Kedrion SpA
• LFB SA
• Bio Products Laboratory Ltd.
• Shanghai RAAS Blood Products Co., Ltd.
• Haema AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Plasma Protein Therapeutics Market is projected to expand from USD 33.26 Billion in 2025 to USD 49.27 Billion by 2031, reflecting a CAGR of 6.77%. These biologic medicines, obtained through the fractionation of human blood plasma, are essential for managing rare and chronic life-threatening diseases such as primary immunodeficiencies and hemophilia. Market expansion is primarily fueled by the rising diagnosis of neurological and immunological disorders that necessitate lifelong replacement therapies, coupled with an aging global population requiring ongoing medical care. Additionally, progress in diagnostic technologies continues to widen the identified patient base, demanding a steady increase in production independent of transient consumption patterns.

A major obstacle hindering wider market growth is the difficulty of sustaining a robust supply chain, which currently depends heavily on a few specific geographic areas for raw material collection. This concentration exposes the industry to risks from regulatory shifts or logistical interruptions that could jeopardize global supply availability. According to the Plasma Protein Therapeutics Association, North American donors contributed over 63% of the world's plasma supply for manufacturing in 2025. As a result, attaining regional self-sufficiency remains a significant barrier to stabilizing the market and satisfying increasing international requirements.

Market Driver

The rising global demand for immunoglobulin therapies serves as a primary growth engine, spurred by the increasing use of immunoglobulins (IG) for treating primary and secondary immunodeficiencies. With improved diagnostic rates and clinical applications expanding to neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), patient dependence on these lifelong treatments has grown significantly. Manufacturers are observing strong adoption of both intravenous and subcutaneous formulations, requiring increased output to avoid shortages for the growing patient population. Highlighting this trend, CSL Limited reported in its 'Half Year Results 2025' from February 2025 that its immunoglobulin portfolio achieved sales of $3.17 billion, marking a 15% rise from the prior period, which underscores the vital role of IG products in the financial growth of key market players.

Simultaneously, the expansion of global plasma collection infrastructure is essential as the industry scales to secure the raw materials needed for fractionation. Companies are making substantial investments to broaden their donor center networks and refine supply chain logistics, aiming to reduce regional reliance and boost collection yields. This structural development is crucial for stabilizing the plasma volume required to manufacture therapies like coagulation factors and albumin. For instance, Forbes noted in a February 2025 article, 'Inside Takeda's Plasma-Derived Therapy Ecosystem', that Takeda now collects over 15 million liters of plasma annually to meet production demands. Furthermore, the market's overall financial resilience is evident, with Grifols reporting total annual revenues of €7.2 billion in its 'Fourth Quarter and Full Year 2024 Results' released in February 2025.

Market Challenge

The primary obstacle constraining the Global Plasma Protein Therapeutics Market is the instability of its supply chain, which is defined by an excessive dependence on a select few geographic regions for source plasma collection. This concentrated reliance establishes a risky bottleneck where global product availability is disproportionately linked to the operational continuity of a single region. Consequently, any local policy changes or logistical disruptions in this primary source area could precipitate worldwide shortages, thereby hindering manufacturers from scaling up production to reliably meet the growing demand for life-saving treatments.

This severe infrastructure imbalance significantly impedes the industry's efforts to diversify its raw material origins. Data from the Plasma Protein Therapeutics Association highlights this disparity; in 2024, the collection landscape was so uneven that the state of Texas alone maintained 178 plasma centers, exceeding the 177 centers found throughout the entire continent of Europe. Such a stark contrast emphasizes the market's susceptibility to regional limitations. Until collection capacity becomes less geographically restricted, the industry will struggle to secure the resilient supply volumes required to sustain global market expansion.

Market Trends

The shift toward subcutaneous immunoglobulin administration is fundamentally altering the market by moving treatment from clinical environments to flexible home-based care settings. This transition is driven by the creation of high-concentration formulations that enable patients with primary immunodeficiencies to self-administer their treatments, greatly enhancing quality of life while decreasing the logistical strain on hospitals. The growing preference for these convenient dosing options is fueling specific growth within the immunoglobulin sector, surpassing traditional intravenous methods as manufacturers launch user-friendly delivery systems. According to CSL Limited's 'Half Year Results 2025' from February 2025, sales of the subcutaneous product HIZENTRA rose by 16% over the previous period, spurred specifically by the robust adoption of pre-filled syringe options.

At the same time, the adoption of advanced chromatographic fractionation techniques is emerging as a critical trend as manufacturers aim to maximize protein recovery from every liter of collected plasma. Confronted with elevated raw material costs, companies are rapidly integrating automated purification processes to boost the yield of valuable proteins, effectively decoupling production volumes from linear collection growth. This strategic emphasis on operational efficiency allows producers to reduce the cost per gram of protein and enhance profitability despite donor market volatility. As reported in Grifols' 'Fourth Quarter and Full Year 2024 Results' in February 2025, the company attained an Adjusted EBITDA margin of 26.6% in the fourth quarter, a result largely credited to ongoing yield improvements and the successful implementation of its operational optimization strategy.

Key Market Players

• Grifols, S.A.
• CSL Behring AG
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxalta Incorporated
• Kedrion S.p.A.
• LFB S.A.
• Bio Products Laboratory Ltd.
• Shanghai RAAS Blood Products Co., Ltd.
• Haema AG

Report Scope

In this report, the Global Plasma Protein Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plasma Protein Therapeutics Market, By Product

• Immunoglobulin
• Albumin
• Plasma Derived Clotting Factor
• Fibrinogen
• Others

Plasma Protein Therapeutics Market, By Application

• Hemophilia
• Primary Immunodeficiency Disorder (PID)
• Idiopathic Thrombocytopenic Purpura (ITP)
• Others

Plasma Protein Therapeutics Market, By End User

• Hospitals
• Research Laboratories and Institutions
• Stand-Alone Blood Banks
• Others

Plasma Protein Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasma Protein Therapeutics Market.

Available Customizations:

Global Plasma Protein Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plasma Protein Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Immunoglobulin, Albumin, Plasma Derived Clotting Factor, Fibrinogen, Others)
  • 5.2.2. By Application (Hemophilia, Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura (ITP), Others)
  • 5.2.3. By End User (Hospitals, Research Laboratories and Institutions, Stand-Alone Blood Banks, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Plasma Protein Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Plasma Protein Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Plasma Protein Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Plasma Protein Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Plasma Protein Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Plasma Protein Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Plasma Protein Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Plasma Protein Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Plasma Protein Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Plasma Protein Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Plasma Protein Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Plasma Protein Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Plasma Protein Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Plasma Protein Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Plasma Protein Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Plasma Protein Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Plasma Protein Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Plasma Protein Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Plasma Protein Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Plasma Protein Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Plasma Protein Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Plasma Protein Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Plasma Protein Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Plasma Protein Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Plasma Protein Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Grifols, S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. CSL Behring AG
• 15.3. Octapharma AG
• 15.4. Takeda Pharmaceutical Company Limited
• 15.5. Baxalta Incorporated
• 15.6. Kedrion S.p.A.
• 15.7. LFB S.A.
• 15.8. Bio Products Laboratory Ltd.
• 15.9. Shanghai RAAS Blood Products Co., Ltd.
• 15.10. Haema AG

16. Strategic Recommendations

17. About Us & Disclaimer